摘要
目的:探讨安罗替尼联合同步放化疗对局部晚期食管癌的治疗效果及安全性分析。方法:选取2019-01-01到2020-04-30间我院收治的252例接受同步放化疗的局部晚期食管癌患者作为回顾性分析研究对象,其中21例加用盐酸安罗替尼药物联合同步放化疗方案,231例采用无盐酸安罗替尼的常规同步放化疗方案,利用倾向评分匹配(Propensity Score Matching, PSM)方法排除年龄、性别等非研究因素的干扰,最终入组42名病人(21名采用“安罗替尼 + 同步放化疗”方案,21名采用“常规同步放化疗”方案),分别在治疗后第12周、24周、36周、48周、60周对患者进行疗效评价及不良反应评估,并跟踪统计两组患者食管癌的局部控制率。结果:安罗替尼联合同步放化疗方案组患者肿瘤局部控制率显著优于常规同步放化疗组患者(P 【0.05)。安罗替尼组患者常见不良的反应为手足综合征(HFS),安罗替尼组的患者手足综合征分级均为II级以下。常规同步放化疗方案组患者的主要不良反应为放射性食管炎及放射性肺炎。结论:安罗替尼联合同步放化疗较常规同步放化疗方案可明显提高食管癌局部晚期患者的肿瘤局部控制率,改善治疗效果。
Objective: To investigate the efficacy and safety of anlotinib combined with CCRT in the treatment of locally advanced esophageal cancer. Methods: 252 patients with locally advanced esophageal cancer who received CCRT in our hospital from 2019-01-01 to 2020-04-30 were selected as subjects for retrospective analysis. Among them, 21 cases were treated with anlotinib hydrochloride combined with CCRT and chemotherapy, and 231 cases were treated with conventional concurrent chemoradiotherapy without anlotinib hydrochloride. The Propensity Score Matching (PSM) method was used to eliminate the interference of age, sex and other non-research factors. Finally, 42 patients were enrolled in the group (21 patients were treated with “anlotinib + CCRT” and 21 patients were treated with “conventional concurrent chemoradiotherapy”). The curative effect and adverse reactions were evaluated at 12 weeks, 24 weeks, 36 weeks, 48 weeks and 60 weeks after treatment, and the local control rate of esophageal cancer in the two groups was followed up. Conclusion: Compared with conventional concurrent chemoradiotherapy, anlotinib combined with CCRT can significantly improve the local control rate and therapeutic effect of patients with locally advanced esophageal cancer.
出处
《临床医学进展》
2020年第8期1766-1772,共7页
Advances in Clinical Medicine
关键词
食管癌
安罗替尼
同步放化疗
局部控制率
Esophageal Carcinoma
Anlotinib
Concurrent Chemoradiotherapy (CCRT)
Local Control Rate
